Search Results - "Tomašević, Z."

Long-term trastuzumab treatment in HER2 positive metastatic breast cancer by Calamac, M., Minic, I., Tomasevic, Z., Oblakovic-Babic, J., Serovic, K., Djurmez, O., Dimitrijevic, M., Bozovic-Spasojevic, I.

Get full text

Tolerability of luteinising hormone releasing hormoneanalogue (LHRH) therapy in patients with early breast cancer treatedat the Institute for Oncology and Radiology of Serbia (IORS) by Dimitrijevic, M., Calamac, M., Djurmez, O., Šerovic, K., Minic, I., Oblakovic, J., Tomaševic, Z., Bozovic Spasojevic, I.

Get full text

Our experience with COVID-19 infection in oncology patients by Djurmez, O., Calamac, M., Dimitrijevic, M., Serovic, K., Oblakovic-Babic, J., Minic, I., Tomasevic, Z., Bozovic-Spasojevic, I.

Get full text

Characteristics of Patients with Breast Cancer (BC) Brain Metastases (BM): Are There Any Clues for Earlier BM Diagnostic Strategies? by Tomasevic, Z.I., Kovac, Z., Tomasevic, Z.

Get full text

HER-Seq: A blood-based genomic screening study to identify HER2 mutation-positive patients for enrollment into clinical trials with the pan-HER inhibitor neratinib by Tomasevic, Z., Smyth, L.M., Saura, C., Boni, V., Garcia-Sáenz, J.Á., Prat, A., Eli, L., Garza, S.J., Lalani, A.S., Crown, J.P.

Get full text

Her 2 3+ Locally Advanced Breast Cancer and Brain Metastases by Tomasevic, Z.I., Tomasevic, Z.M., Kovac, Z.

Get full text

Histology and molecular characteristics of pregnancy associated breast cancer by Tomasevic, Z., Milovanovic, Z., Tomasevic, Z.M., Bozovic Spasojevic, I., Milosevic, S., Zdrale, Z., Andjelic Dekic, N., Kovac, Z.

Get full text

5077 POSTER Inflammatory Breast Cancer (IBC): Does the Confirmation of Dermal Lymphatic Invasion (DLI) Predict the Worst Outcome? by Kolarevic, D, Tomasevic, Z

Get full text

HER2 status of breast carcinoma developed as a secondary malignancy after Hodgkin lymphoma treatment by Tomasevic, Z. M., Kolarevic, D., Tomasevic, Z., Milovanovic, Z.

“…Abstract only…”
Get full text

74 Breast Cancers as a Secondary Malignancy After Treatment for Hodgkin Lymphoma – Focus on HER2 Status by Tomasevic, Z, Kolarevic, D, Tomasevic, Z.M, Milovanovic, Z

Get full text

19P LUNG CANCER AS A SECOND MALIGNANCY AFTER INITIAL TREATMENT OF PRIMARY NON LUNG CANCER – A SINGLE INSTITUTION EXPERIENCE by Nikolic, N, Tomasevic, Z, Radosavljevic, D, Dimitrijevic, J, Nikolic, V

Get full text

877: Changes of the white blood cells subsets in HER2 positive breast cancer patients treated with trastuzumab by Matic, I, Grujic, M, Kolundzija, B, Damjanovic Velickovic, A, Tomasevic, Z, Bozovic Spasojevic, I, Dzodic, R, Zdrale, Z, Juranic, Z

Get full text

C0219: The Presence of Prothrombotic Mutations and a Higher FVIII Activity Contribute to Thrombosis Development During the Breast Cancer Treatment by Kovac, M, Pruner, I, Kovac, Z, Tomasevic, Z, Djordjevic, V, Radojkovic, D

Get full text

Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients? by Tomasevic, Z I, Rakocevic, Z, Tomasevic, Z M, Milovanovic, Z, Inic, M, Kolarevic, D, Lukic, V, Kovac, Z

“…Human epidermal growth factor receptor 2 overexpression (HER2 3+) is reported in retrospective studies as a factor that contributes to higher incidence of…”
Get more information

5105 POSTER Assessing the Cognitive Function Among the Breast Cancer Patient After Chemotherapy Treatment by Matijasevic, M, Zdrale, Z, Milosevic, S, Tomasevic, Z

Get full text

Comparison of hormone receptor and HER2 status in resected brain metastases and primary breast cancer by Tomasevic, Z., Milovanovic, Z., Tomasevic, Z. M., Skender, M., Pupic, G., Kovac, Z., Grujicic, D.

“…Abstract only…”
Get full text

PO34 Clinico-pathologic features of young breast cancer patients treated at the Institute for Oncology and Radiology of Serbia by Bozovic-Spasojevic, I, Susnjar, S, Neskovic-Konstantinovic, Z, Andjelic-Dekic, N, Milosevic, S, Tomasevic, Z

Get full text

Late relapse in triple negative breast cancer by Tomasevic, Z., Radosevic-jelic, L., Tomasevic, Z. M., Jelic, S., Milovanovic, Z.

“…Abstract only e12022 Background: Approximately 10%-15 % breast cancer (BC) are classified as triple negative. Although triple negative status carries grave…”
Get full text

Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer by Zegarac, M, Nikolic, S, Gavrilovic, D, Jevric, M, Kolarevic, D, Nikolic-Tomasevic, Z, Kocic, M, Djurisic, I, Inic, Z, Ilic, V, Santrac, N

“…Isolated liver metastases (LMs) from breast cancer (BC) occur in only 1-3% of the cases. Resection of isolated LMs improves survival. We examined the…”
Get more information

Fluoropyrimidine therapy : hyperbilirubinemia as a consequence of hemolysis by NIKOLIC-TOMASEVIC, Z, JELIC, S, CASSIDY, J, FILIPOVIC-LJESKOVIC, I, TOMASEVIC, Z

“…Hemolytic anemia has been noted during treatment with a variety of chemotherapeutic agents. We observed mild compensated hemolytic anemia in a patient…”
Get full text